The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials
Semaglutide represents a promising pharmacotherapeutic option for MASH, demonstrating significant improvements in histologic resolution, liver injury biomarkers, and metabolic parameters, particularly at higher doses and longer intervention durations, though its effect on fibrosis regression remains limited.
Authors
- Danpei Li (ORCID: https://orcid.org/0000-0003-4972-976X)
- Xiaoyu Meng (ORCID: https://orcid.org/0000-0002-5239-6866)
- Yaming Guo
- Ranran Kan (ORCID: https://orcid.org/0009-0001-2829-945X)
- Xuefeng Yu (ORCID: https://orcid.org/0000-0003-4349-4015)
- Siyi Wang (ORCID: https://orcid.org/0009-0006-4909-2569)
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- National Clinical Research (US)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1186/s13098-025-01995-z
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Natural Science Foundation of China